AngioDynamics Company Leadership

AngioDynamics' latest congressional trading

AngioDynamics Management Team Effectiveness

The company has return on total asset (ROA) of (0.046) % which means that it has lost $0.046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1526) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of January 2026, Return On Tangible Assets is likely to grow to -0.18. In addition to that, Return On Capital Employed is likely to grow to -0.21. At this time, AngioDynamics' Total Assets are very stable compared to the past year. As of the 29th of January 2026, Other Assets is likely to grow to about 59.4 M, while Non Current Assets Total are likely to drop about 122.2 M. As of the 29th of January 2026, Common Stock Shares Outstanding is likely to drop to about 30.6 M. In addition to that, Net Loss is likely to grow to about (44.8 M)AngioDynamics holds a total of 41.22 Million outstanding shares. The majority of AngioDynamics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AngioDynamics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AngioDynamics. Please pay attention to any change in the institutional holdings of AngioDynamics as this could imply that something significant has changed or is about to change at the company. On October 27, 2025, Representative Debbie Wasserman Schultz of US Congress acquired under $15k worth of AngioDynamics's common stock. Some institutional investors establish a significant position in stocks such as AngioDynamics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of AngioDynamics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

AngioDynamics Workforce Comparison

AngioDynamics Profit Margins

The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.03) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.03.

AngioDynamics Insider Trading History

AngioDynamics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as AngioDynamics often depends on how effective the management is. AngioDynamics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AngioDynamics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AngioDynamics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Will Health Care Equipment & Supplies sector continue expanding? Could AngioDynamics diversify its offerings? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AngioDynamics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Investors evaluate AngioDynamics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating AngioDynamics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause AngioDynamics' market price to deviate significantly from intrinsic value.

Understanding that AngioDynamics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AngioDynamics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, AngioDynamics' market price signifies the transaction level at which participants voluntarily complete trades.